| Patient apps for improved healthcare: from novelty to mainstream M Aitken, C Gauntlett Parsippany, NJ: IMS Institute for Healthcare Informatics 201 (3), 2013 | 238 | 2013 |
| Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point: The drug spending trends observed in the 1980s, 1990s, and the first few years of this�… M Aitken, ER Berndt, DM Cutler Health Affairs 27 (Suppl1), w151-w160, 2008 | 205 | 2008 |
| Patient adoption of mHealth: use, evidence and remaining barriers to mainstream acceptance M Aitken, J Lyle Parsippany, NJ: IMS Institute for Healthcare Informatics 2, 2015 | 191 | 2015 |
| Advancing the responsible use of medicines: applying levers for change M Aitken, L Gorokhovich Available at SSRN 2222541, 2012 | 191 | 2012 |
| Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation ER Berndt, ML Aitken International Journal of the Economics of Business 18 (2), 177-201, 2011 | 189 | 2011 |
| The growing value of digital health: evidence and impact on human health and the healthcare system M Aitken, B Clancy, D Nass IQVIA Institute for Human Data Science 1, 2017 | 153 | 2017 |
| Decline in economic returns from new drugs raises questions about sustaining innovations ER Berndt, D Nass, M Kleinrock, M Aitken Health Affairs 34 (2), 245-252, 2015 | 103 | 2015 |
| Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study S Jayawardana, R Forman, C Johnston-Webber, A Campbell, ... EClinicalMedicine 42, 2021 | 90 | 2021 |
| Medicines use and spending in the US: a review of 2016 and outlook to 2021 M Aitken, M Kleinrock, K Pennente, J Lyle, D Nass, L Caskey Parsippany: IMS Institute for Healthcare Informatics, 2016 | 73 | 2016 |
| Avoidable costs in US healthcare: the $200 billion opportunity from using medicines more responsibly M Aitken, S Valkova IMS Institute for Healthcare Informatics, 27-29, 2013 | 73 | 2013 |
| The global use of medicine in 2019 and outlook to 2023 M Aitken, M Kleinrock, A Simorellis, D Nass IQVIA Institute for Human Data Science 1, 2019 | 65 | 2019 |
| Global medicines use in 2020: outlook and implications M Aitken, M Kleinrock USA: Parsippany, New Jersey, 2015 | 63 | 2015 |
| Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013 M Aitken, M Kleinrock, J Lyle, L Caskey IMS Institute for Healthcare Informatics, 2014 | 63 | 2014 |
| Medicines use and spending shifts: a review of the use of medicines in the US in 2014 M Aitken, M Kleinrock, J Lyle, D Nass, L Caskey IMS Institute for Healthcare Informatics, 2015 | 60 | 2015 |
| Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? MR Trusheim, ML Aitken, ER Berndt Forum for health economics & policy 13 (1), 2010 | 60 | 2010 |
| Understanding the pharmaceutical value chain M Aitken Pharmaceuticals Policy and Law 18 (1-4), 55-66, 2016 | 54 | 2016 |
| Digital health trends 2021: innovation, evidence, regulation, and adoption M Aitken, D Nass IQVIA Institute for Human Data Science, 2022-10, 2021 | 52 | 2021 |
| Engaging patients through social media M Aitken, T Altmann, D Rosen Parsippany (NJ): IMS Institute for Healthcare Informatics, 2014 | 50 | 2014 |
| Has the era of slow growth for prescription drug spending ended? M Aitken, ER Berndt, D Cutler, M Kleinrock, L Maini Health Affairs 35 (9), 1595-1603, 2016 | 45 | 2016 |
| Delivering on the potential of biosimilar medicines. The role of functioning competitive markets M Aitken IMS Institute for Healthcare Informatics, 2016 | 42 | 2016 |
David CutlerOtto Eckstein Professor of Applied Economics, Harvard UniversityVerified email at harvard.edu
